Chime Biologics, Hope Medicine Strike Manufacturing Deal
Agreement aims to speed up the launch of endometriosis and androgenic alopecia treatment.
Chime Biologics, a contract development and manufacturing organization (CDMO), and Hope Medicine, a clinical-stage biotech company, announced plans to collaborate on development and manufacturing of monoclonal antibody drug HMI-115. As per the agreement, Chime Biologics will provide CMC solution for the biotech’s drug candidate, hoping to speed up the process of a potential launch for treatment of endometriosis and androgenetic alopecia.
"We are pleased to be a strategic partner of Hope Medicine. We are fully committed to driving the commercialization of HMI-115 mAb for the treatment of endometriosis and androgenetic alopecia to ensure the successful launch of this novel antibody drug,” said Jimmy Wei, president, Chime Biologics. “Currently, Chime Biologics has completed several late-stage CMC projects and is also in the process of commercial manufacturing for several post-market drugs. We are proud to empower our global partners to deliver clinical value for the benefit of patients."
Reference: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia. PR Newswire. October 26, 2023. Accessed October 26, 2023. https://www.prnewswire.com/news-releases/chime-biologics-and-hope-medicine-enter-manufacturing-agreement-to-speed-up-the-launch-of-first-in-class-antibody-drug-hmi-115-targeting-endometriosis-and-androgenic-alopecia-301968968.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
